Androgen Receptor-Induced Integrin α6β1 and Bnip3 Promotes Survival and Resistance to PI3K Inhibitors in Castration-Resistant Prostate Cancer

The androgen receptor (AR) is the major driver of prostate cancer growth and survival. However, almost all patients relapse with castration resistant disease (CRPC) when treated with anti-androgen therapy. In CRPC, AR is often aberrantly activated independent of androgen. Targeting survival pathways...

Descripción completa

Detalles Bibliográficos
Autores principales: Nollet, Eric A., Cardo-Vila, Marina, Ganguly, Sourik S., Tran, Jack D., Schulz, Veronique V., Cress, Anne, Corey, Eva, Miranti, Cindy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395876/
https://www.ncbi.nlm.nih.gov/pubmed/32565538
http://dx.doi.org/10.1038/s41388-020-1370-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395876/
https://www.ncbi.nlm.nih.gov/pubmed/32565538
http://dx.doi.org/10.1038/s41388-020-1370-9

Ejemplares similares